))
LARVOL Onco Data Podcast with Dr. Amol Akhade & Dr. Guru Sonpavde | Post-ESMO | E.32
Manage episode 444078348 series 3606267
Content provided by Bruno Larvol, Mark Gramling, Bruno Larvol, and Mark Gramling. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bruno Larvol, Mark Gramling, Bruno Larvol, and Mark Gramling or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
In this engaging episode of the LARVOL Onco Data Podcast, Guru Sonpavde, MD, and Dr. Amol Akhade delve into key takeaways from the latest oncology discussions at ESMO24. The conversation highlights the expanding treatment options for physicians. Our VP of Oncology, Dr. Mark Gramling, emphasized the importance of focusing on the optimal sequencing of treatments like Ambassador, Niagara, EV-302, and Litespark. While more study is needed to determine the best approach, having these additional options is a win for patient care. Dr. Guru shares his thoughts on these important trials and how they have shaped recent discussions in GU cancer research. Dr. Amol adds his perspective on the significance of these trials and the need for continued research. As the episode wraps up, both experts emphasize the value of ongoing collaboration and research, promising more in-depth discussions in the future. Don’t miss out on this lively exchange of insights into the latest advancements in urologic oncology! Check out clin.larvol.com for more oncology data, and don’t forget to follow Dr. Guru and Dr. Amol on social media for updates on future trials. #ESMO24 #GUOncology #AmbassadorTrial #NiagaraTrial #EV302 #Litespark #Oncology #LARVOL
32 episoade
Distribuie
